Antibac Soap Decline Likely In Reaction To Triclosan Debate
This article was originally published in The Rose Sheet
FDA’s recent proposal to amend the OTC antiseptic drug product monograph could impact sales of antibacterial soaps, according to analysts from market research firm Kline & Company. Firms will “likely choose the path of least resistance” and replace controversial ingredient triclosan, they predict.
You may also be interested in...
Minnesota Governor Mark Dayton has signed a bill that will ban personal cleansing products that contain triclosan from sale in the state, beginning Jan. 1, 2017. The legislation exempts products approved for consumer use by FDA, which currently is reevaluating the safety and efficacy of ingredients in antibacterial soaps used by consumers.
A study funded in part by the Personal Care Products Council found use of antibacterial treatments to reduce concentrations of Shigella bacteria on participants’ hands significantly, leading to reduced levels transferred to melon balls and compelling estimates of reduced illness in eaters. FDA has requested such data as it considers GRASE conditions for antibacterial washes under a proposed rule issued in December 2013 that could require manufacturers to reformulate and relabel products.
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.